Fulcrum Therapeutics Inc (NASDAQ:FULC) shares, rose in value on Friday, June 20, with the stock price up by 9.98% to the previous day’s close as strong demand from buyers drove the stock to $6.99.
Actively observing the price movement in the last trading, the stock closed the session at $6.36, falling within a range of $6.32 and $7.21. The value of beta (5-year monthly) was 2.42. Referring to stock’s 52-week performance, its high was $10.13, and the low was $2.32. On the whole, FULC has fluctuated by 7.45% over the past month.
With the market capitalization of Fulcrum Therapeutics Inc currently standing at about $377.59 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-01.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that FULC’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of FULC currently trading nearly 2.71% and 28.25% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 60.79, while the 7-day volatility ratio is showing 6.39% which for the 30-day chart, stands at 3.67%. Furthermore, Fulcrum Therapeutics Inc (FULC)’s beta value is 2.42, and its average true range (ATR) is 0.49.
A comparison of Fulcrum Therapeutics Inc (FULC) with its peers suggests the former has fared considerably weaker in the market. FULC showed an intraday change of 9.98% in last session, and over the past year, it shrunk by -0.07%%.
Data on historical trading for Fulcrum Therapeutics Inc (NASDAQ:FULC) indicates that the trading volumes over the past 10 days have averaged 0.44 and over the past 3 months, they’ve averaged 551.64K. According to company’s latest data on outstanding shares, there are 53.98 million shares outstanding.
Nearly 11.36% of Fulcrum Therapeutics Inc’s shares belong to company insiders and institutional investors own 85.60% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.68 million shares as on 2025-05-30, resulting in a short ratio of 6.39. According to the data, the short interest in Fulcrum Therapeutics Inc (FULC) stood at 1521.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 3.4 million. The stock has risen by 48.83% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the FULC stock heading into the next quarter.
